Department of Pediatric Infectious Diseases, University of Health Sciences Dr. Behçet Uz Children's Hospital, Konak, 35210, İzmir, Turkey.
Department of Pediatrics, University of Health Sciences Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
Pediatr Cardiol. 2023 Apr;44(4):873-881. doi: 10.1007/s00246-022-03017-5. Epub 2022 Oct 9.
Children with COVID-19 usually show milder symptoms than adults; however, a minority of them may have cardiac involvement. We aimed to identify the role of troponin I levels that may predict early cardiac involvement in children with COVID-19. A single-center retrospective study was conducted to evaluate hospitalized children diagnosed with COVID-19 between March 11, 2020, and December 31, 2021. Patients with available troponin I levels and with no known cardiac disease were included. During the study period, 412 children with COVID-19 who had troponin I levels on admission were identified. Troponin levels were elevated in 7 (1.7%) patients and were normal in 395 (98.3%) patients. The median age of patients with elevated troponin levels was 4 (min. 2-max. 144) months, which was statistically lower than the age of patients with normal troponin levels (P = 0.035). All the patients with elevated troponin levels had tachycardia. Out of 7 patients with high troponin levels, 3 (42.9%) of them were admitted to the pediatric intensive care unit (PICU), 2 (28.6%) required oxygen support, and 1 (14.3%) required a mechanical ventilator. Patients with elevated troponin levels had a statistically longer hospital stay (P < 0.001). Neutropenia, tachycardia, PICU admission, oxygen support, and mechanical ventilation were statistically more common in patients with elevated troponin levels (P values were 0.033, 0.020, < 0.001, 0.050, and < 0.001, respectively). Electrocardiography (ECG) and echocardiography (ECHO) were performed on all patients with elevated troponin levels, and 6 (85.8%) patients were diagnosed with myocarditis. The ECG and ECHO have been performed in 58 (14.3%) out of 405 patients with normal troponin levels. Two (3.5%) patients had negative T waves on ECG, and all ECHOs were normal. Our results suggest that elevated troponin I levels in children with COVID-19 can be used to evaluate cardiac involvement and decide the need for further pediatric cardiologist evaluation.
儿童感染 COVID-19 的症状通常比成年人轻,但少数儿童可能存在心脏受累。我们旨在确定肌钙蛋白 I 水平的作用,该水平可能预测 COVID-19 患儿的早期心脏受累。
进行了一项单中心回顾性研究,以评估 2020 年 3 月 11 日至 2021 年 12 月 31 日期间住院的确诊 COVID-19 的儿童。纳入了有肌钙蛋白 I 水平且无已知心脏病的患者。
在研究期间,确定了 412 名入院时肌钙蛋白 I 水平升高的 COVID-19 患儿。7 名患者的肌钙蛋白水平升高,395 名患者(98.3%)的肌钙蛋白水平正常。肌钙蛋白水平升高的患者的中位年龄为 4 个月(最小 2 岁-最大 144 岁),明显低于肌钙蛋白水平正常的患者(P=0.035)。所有肌钙蛋白水平升高的患者均有心悸。7 名肌钙蛋白水平升高的患者中,3 名(42.9%)患者入住儿科重症监护病房(PICU),2 名(28.6%)需要氧疗,1 名(14.3%)需要机械通气。
肌钙蛋白水平升高的患者的住院时间明显延长(P<0.001)。中性粒细胞减少症、心动过速、入住 PICU、氧疗和机械通气在肌钙蛋白水平升高的患者中更为常见(P 值分别为 0.033、0.020、<0.001、0.050 和<0.001)。
所有肌钙蛋白水平升高的患者均进行了心电图(ECG)和超声心动图(ECHO)检查,其中 6 名(85.8%)患者被诊断为心肌炎。在 405 名肌钙蛋白水平正常的患者中,有 58 名(14.3%)进行了心电图和超声心动图检查。2 名(3.5%)患者的心电图有负 T 波,所有的超声心动图均正常。
我们的结果表明,COVID-19 患儿肌钙蛋白 I 水平升高可用于评估心脏受累情况,并决定是否需要进一步儿科心脏病专家评估。